ArticlePharmacoEconomics - open2025
Cost Effectiveness of Recombinant Zoster Vaccine and Live-Attenuated Vaccine Against Herpes Zoster for Adults Aged 50 and Over in China.
Article in PharmacoEconomics - open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTwo vaccines against herpes zoster (HZ) are currently authorized for use in China: the adjuvanted recombinant zoster vaccine (RZV) and live-attenuated Zoster Vaccine Live (ZVL). The significant disparities in prices and efficacy between the two vaccines necessitate an evaluation of their relative value in order to make an informed choice. This study aimed to evaluate the comparative cost effectiveness of RZV, ZVL, and no vaccination for older adults at different ages from the societal perspective.
methodsThe Markov decision model was parameterized using vaccine efficacy data, the latest incidence rates, costs, and health-related quality-of-life data. Participants consisted of a cohort comprising adults aged ≥ 50 years in China. The lifetime health impacts, cost, life-year (LY), quality-adjusted life-year (QALY) gained and the incremental cost-effectiveness ratio (ICER), net monetary benefits (NMB), net health benefits (NHB), and expected value of perfect information (EVPI) were calculated. Sensitivity analyses, scenario analyses, and subgroup analyses were performed.
resultsCompared with no vaccination, RZV and ZVL could avoid 2,009,292 versus 510,192 HZ cases, and 334,637 versus 90,996 post-herpetic neuralgia (PHN) cases in the overall cohort, respectively. RZV and ZVL were more costly by US$1624 million versus US$896 million compared with no vaccination, with an additional 58,180 versus 23,390 QALYs. At threefold gross domestic product per capita, RZV had cost-effectiveness probabilities of 47.37% for ages 50-59 years, 83.24% for ages 60-69 years, 28.28% for ages 70-79 years, and 51.93% for ages ≥ 80 years, while ZVL had 7.07%, 12.79%, 69.55%, 2.82% probability, and no vaccination had 45.56%, 3.97%, 2.17%, 45.25% probability of being cost effective for the corresponding age cohorts.
conclusionsThe strategy utilizing RZV demonstrated superior efficacy in reducing the burden of HZ compared with ZVL. RZV was most cost effective in the 50-59, 60-69 and ≥ 80 years age groups, and ZVL was most cost effective in the 70-79 years group.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.